ES2170050T3 - Metodos y composiciones para inducir la ereccion. - Google Patents

Metodos y composiciones para inducir la ereccion.

Info

Publication number
ES2170050T3
ES2170050T3 ES90914620T ES90914620T ES2170050T3 ES 2170050 T3 ES2170050 T3 ES 2170050T3 ES 90914620 T ES90914620 T ES 90914620T ES 90914620 T ES90914620 T ES 90914620T ES 2170050 T3 ES2170050 T3 ES 2170050T3
Authority
ES
Spain
Prior art keywords
male
peptide
impotence
terminal
methionineamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90914620T
Other languages
English (en)
Inventor
Thomas Gerstenberg
Jan Fahrenkrug
Bent Ottesen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Senetek PLC
Original Assignee
Senetek PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senetek PLC filed Critical Senetek PLC
Application granted granted Critical
Publication of ES2170050T3 publication Critical patent/ES2170050T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants

Abstract

ESTA INVENCION PROPORCIONA METODOS Y COMPOSICIONES PARA INDUCIR A UN HOMBRE QUE SUFRE DE IMPOTENCIA, ERECCIONES DEL PENE SUFICIENTES PARA LA PENETRACION VAGINAL. CUANDO LA IMPOTENCIA SOLO ES SUSTANCIALMENTE NEUROGENICA SICOGENICA O NEUROGENICA Y SICOGENICA, UN METODO DE LA INVENCION COMPRENDE (A) ADMINISTRAR AL HOMBRE MEDIANTE UNA INYECCION INTRACAVERNOSA PEPTIDO N-TERMINAL HISTIDINA C-TERMINAL METIONINEAMIDA Y (B) ESTIMULAR AL HOMBRE SEXUALMENTE. CUANDO LA IMPOTENCIA ESTA CAUSADA POR UNA ARTEROESCLEROSIS SEVERA, UN METODO DE LA INVENCION COMPRENDE (A) ADMINISTRAR AL HOMBRE MEDIANTE UNA INYECCION INTRACAVERNOSA UNA CANTIDAD DE UNA COMPOSICION FISIOLOGICAMENTE ACEPTABLE QUE COMPRENDE (I) UN NEUROPEPTIDO SELECCIONADO DEL GRUPO QUE CONSISTE EN PEPTIDO INTESTINAL VASOACTIVO HUMANO Y PEPTIDO N-TERMINAL HISTIDINE C-TERMINAL METIONINEAMIDA Y (2) UN BLOQUEADOR ALFA-ADRENERGICO, TAL COMO FEUTOLAMINA O PRAZOSINA, Y (B) ESTIMULAR SEXUALMENTE AL HOMBRE. LA INVENCION INCLUYE TAMBIEN UNA COMPOSICION FISIOLOGICAMENTE ACEPTABLE APROPIADA PARA UTILIZAR EN LA INDUCCION, DESPUES DE LA ADMINISTRACION A UN HOMBRE QUE SUFRE DE IMPOTENCIA INYECCION INTRACAVERNOSA, DE UNA ERECCION, SUFICIENTE PARA LA PENETRACION VAGINAL, CUANDO LA IMPOTENCIA ES OCASIONADA POR UNA SEVERA ARTEROESCLEROSIS, CUYA COMPOSICION COMPRENDE (I) UN NEUROPEPTIDO SELECCIONADO DEL GRUPO QUE CONSISTE EN PEPTIDO INTESTINAL VASOACTIVO Y PEPTIDO N-TERMINAL HISTIDINA C-TERMINAL METIONINEAMIDA Y (2) UN BLOQUEADOR ALFA-ADRENERGICO, TAL COMO FEUTOLAMINA O PAROSINA.
ES90914620T 1989-09-18 1990-09-14 Metodos y composiciones para inducir la ereccion. Expired - Lifetime ES2170050T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/408,754 US5236904A (en) 1989-09-18 1989-09-18 Erection-inducing methods and compositions

Publications (1)

Publication Number Publication Date
ES2170050T3 true ES2170050T3 (es) 2002-08-01

Family

ID=23617626

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90914620T Expired - Lifetime ES2170050T3 (es) 1989-09-18 1990-09-14 Metodos y composiciones para inducir la ereccion.

Country Status (24)

Country Link
US (1) US5236904A (es)
EP (1) EP0493485B1 (es)
JP (1) JP3149946B2 (es)
KR (1) KR100230720B1 (es)
AT (1) ATE210994T1 (es)
AU (1) AU641184B2 (es)
BR (1) BR9007662A (es)
CA (1) CA2065270C (es)
CZ (1) CZ280446B6 (es)
DE (1) DE69033881T2 (es)
DK (1) DK0493485T3 (es)
ES (1) ES2170050T3 (es)
FI (1) FI104231B1 (es)
GE (1) GEP19981264B (es)
HK (1) HK1011292A1 (es)
HU (1) HU208088B (es)
IL (1) IL95505A (es)
LT (1) LT3544B (es)
LV (1) LV10198B (es)
NO (1) NO307498B1 (es)
RO (1) RO116346B1 (es)
RU (1) RU2098120C1 (es)
SK (1) SK279489B6 (es)
WO (1) WO1991004039A1 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5447912A (en) * 1989-09-18 1995-09-05 Senetek, Plc Erection-inducing methods and compositions
US5242391A (en) * 1990-04-25 1993-09-07 Alza Corporation Urethral insert for treatment of erectile dysfunction
DE4117249C2 (de) * 1991-05-27 1998-05-14 Christian Dr Stief Linsidomin zur Behandlung erektiler Dysfunktionen
US5565466A (en) * 1993-08-13 1996-10-15 Zonagen, Inc. Methods for modulating the human sexual response
US5482039A (en) * 1994-03-25 1996-01-09 Vivus, Inc. Process for diagnosing erectile dysfunction, and related methods of treatment
US5583144A (en) * 1995-02-24 1996-12-10 Kral; John G. Methods for treating erectile impotence
US5731339A (en) * 1995-04-28 1998-03-24 Zonagen, Inc. Methods and formulations for modulating the human sexual response
US6294517B1 (en) 1996-02-02 2001-09-25 Nitromed, Inc. Compositions and kits comprising alpha-adrenergic receptor antagonists and nitric oxide donors and methods of use
US5932538A (en) * 1996-02-02 1999-08-03 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
US6469065B1 (en) 1996-02-02 2002-10-22 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist, compositions and methods of use
US20050065161A1 (en) * 1996-02-02 2005-03-24 Nitromed, Inc. Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses
US20020143007A1 (en) * 1996-02-02 2002-10-03 Garvey David S. Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use
US6323211B1 (en) 1996-02-02 2001-11-27 Nitromed, Inc. Compositions and methods for treating sexual dysfunctions
US5994294A (en) * 1996-02-02 1999-11-30 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
US20030004170A1 (en) * 1997-05-19 2003-01-02 Zonagen, Inc. Combination therapy for modulating the human sexual response
US5947901A (en) 1997-09-09 1999-09-07 Redano; Richard T. Method for hemodynamic stimulation and monitoring
US5942545A (en) * 1998-06-15 1999-08-24 Macrochem Corporation Composition and method for treating penile erectile dysfunction
US6011043A (en) * 1998-06-19 2000-01-04 Schering Corporation Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction
US6482426B1 (en) 1998-09-17 2002-11-19 Zonagen, Inc. Compositions for the treatment of male erectile dysfunction
US6706682B2 (en) * 1999-01-21 2004-03-16 The Trustees Of Columbia University In The City Of New York Uses of vascular endothelial growth factor in the treatment of erectile dysfunction
US6730065B1 (en) * 2000-09-15 2004-05-04 Ocularis Pharma, Inc. Night vision composition
US6650943B1 (en) 2000-04-07 2003-11-18 Advanced Bionics Corporation Fully implantable neurostimulator for cavernous nerve stimulation as a therapy for erectile dysfunction and other sexual dysfunction
AU2001259848B2 (en) * 2000-05-12 2005-10-13 Septodont Holding Sas Local anesthetic methods and kits
US20060211753A1 (en) * 2000-11-03 2006-09-21 Ocularis Pharma, Inc. Method and composition which reduces stimulation of muscles which dilate the eye
US6885895B1 (en) * 2001-04-26 2005-04-26 Advanced Bionics Corporation Methods and systems for electrical and/or drug stimulation as a therapy for erectile dysfunction
AU2006222233B2 (en) * 2005-03-07 2011-05-12 Mondobiotech Ag Formulation for aviptadil
US8334257B2 (en) 2005-12-20 2012-12-18 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
EP3412300A1 (en) 2008-06-27 2018-12-12 Duke University Therapeutic agents comprising elastin-like peptides
EP2464370B1 (en) * 2009-08-14 2017-03-29 Phasebio Pharmaceuticals, Inc. Modified vasoactive intestinal peptides
EP2493434A1 (en) 2009-10-30 2012-09-05 Medispec Ltd Method and apparatus for treatment of erectile dysfunction with extracorporeal shockwaves
CA2873553C (en) 2011-06-06 2020-01-28 Phasebio Pharmaceuticals, Inc. Use of modified vasoactive intestinal peptides in the treatment of hypertension
GB201221046D0 (en) * 2012-11-22 2013-01-09 Mens Health Ltd Method of diagnosis
GB201221032D0 (en) * 2012-11-22 2013-01-09 Mens Health Ltd Method of treatment
ES2818824T3 (es) 2014-05-08 2021-04-14 Phasebio Pharmaceuticals Inc Composiciones que comprenden una proteína de fusión de VIP-ELP para su uso en el tratamiento de fibrosis quística
CA2976038A1 (en) 2015-02-09 2016-08-18 Phasebio Pharmaceuticals, Inc. Methods and compositions for treating muscle disease and disorders
WO2019102310A1 (en) 2017-11-24 2019-05-31 Alaval (Pty) Ltd Vip formulation for management of inflammatory conditions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3898329A (en) * 1971-09-17 1975-08-05 Sami I Said Vasoactive intestinal peptide, composition and method
DE3637157A1 (de) * 1985-11-01 1987-05-21 Byk Gulden Lomberg Chem Fab Arzneimittel zur behandlung erektiler dysfunktionen
JPS62246595A (ja) * 1986-04-17 1987-10-27 Eisai Co Ltd 気菅支拡張作用・降圧作用ペプタイド
US4939224A (en) * 1987-02-26 1990-07-03 The Salk Institute Biotechnology/Industrial Associates, Inc. Vasoactive intestinal peptide analogs
IL87055A (en) * 1988-07-08 1994-06-24 Illana Gozes Conjugates of vasoactive intestinal peptide (vip) and of fragments thereof and pharmaceutical compositions comprising them
SE463851B (sv) * 1988-09-02 1991-02-04 Amsu Ltd Komposition foer behandling av erektil dysfunktion via uretra

Also Published As

Publication number Publication date
FI921136A (fi) 1992-03-17
WO1991004039A1 (en) 1991-04-04
RU2098120C1 (ru) 1997-12-10
BR9007662A (pt) 1992-07-21
DE69033881D1 (de) 2002-01-31
DK0493485T3 (da) 2002-03-18
AU641184B2 (en) 1993-09-16
GEP19981264B (en) 1998-07-07
NO920915D0 (no) 1992-03-09
JPH05500513A (ja) 1993-02-04
EP0493485A4 (en) 1993-08-18
SK452490A3 (en) 1998-12-02
HUT60633A (en) 1992-10-28
NO920915L (no) 1992-03-09
LV10198B (en) 1995-08-20
US5236904A (en) 1993-08-17
ATE210994T1 (de) 2002-01-15
FI921136A0 (fi) 1992-03-17
DE69033881T2 (de) 2002-09-12
AU6440490A (en) 1991-04-18
LV10198A (lv) 1994-10-20
RO116346B1 (ro) 2001-01-30
EP0493485A1 (en) 1992-07-08
KR100230720B1 (en) 1999-11-15
IL95505A (en) 1997-03-18
HU208088B (en) 1993-08-30
CA2065270C (en) 2003-01-14
HU9200874D0 (en) 1992-05-28
JP3149946B2 (ja) 2001-03-26
LTIP1579A (en) 1995-06-26
SK279489B6 (sk) 1998-12-02
FI104231B (fi) 1999-12-15
CZ452490A3 (en) 1995-09-13
HK1011292A1 (en) 1999-07-09
NO307498B1 (no) 2000-04-17
LT3544B (en) 1995-11-27
FI104231B1 (fi) 1999-12-15
CZ280446B6 (cs) 1996-01-17
CA2065270A1 (en) 1991-03-19
EP0493485B1 (en) 2001-12-19

Similar Documents

Publication Publication Date Title
ES2170050T3 (es) Metodos y composiciones para inducir la ereccion.
Cohen et al. Somatostatin inhibits adrenergic and cholinergic neurotransmission in smooth muscle
IL112112A0 (en) Peptide derivatives and pharmaceutical compositions containing them
LV10107A (lv) Peptida atvasinajums ta iegusanas metode to satuross farmaceitisks sastavs un glaukomas arstesanas metode
DE69027992D1 (de) Steigerung der fruchtbarkeit
KR937000146A (ko) 거세되지 않은 수컷 가축의 고기의 관능적 품질을 개선하기 위한 방법, 이 방법에 이용 가능한 백신, 특히 그 백신을 생산하기 위한 신규의 펩티드 및 그에 관계된 백신반응 키트
DE59004445D1 (de) Arzneimittel (calcitoningen verwandte peptide) zur behandlung erektiler dysfunktionen.
DK0464124T3 (da) Peptid, immunogen sammensætning og vaccine eller medicinsk præparat, fremgangsmåde til immunisering af et pattedyr mod LHRH og fremgangsmåde til forbedring af kødkvaliteten hos grise
AU625561B2 (en) Method and composition for preventing conception
SE9201425D0 (sv) Method and means for preventing constriction of the pupil in the eye
Jin et al. The effect of bombesin-related peptides on the phagocytic function of mouse phagocytes in vitro
DE69131629D1 (de) Behandlung fehlender milchabsonderung beim menschen
KR920004417A (ko) 고나돌리베린 길항물질
KR920700675A (ko) 발기 기능장해 치료용 약물(칼시토닌 유전자 관련 펩티드)
Ngamvongchon Structure and function of gonadotropin-releasing hormone in the Thai catfish, Clarias macrocephalus
Keogh et al. A Description of the Pioneering Work That Led to the First Approved Agents for ED: Giles Brindley, the Needle, and the Penis (Phenoxybenzamine)
JPS5791965A (en) Preparation of polypeptide

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 493485

Country of ref document: ES